Skip to main content
. Author manuscript; available in PMC: 2023 Feb 15.
Published in final edited form as: Am J Cardiol. 2021 Dec 20;165:124–130. doi: 10.1016/j.amjcard.2021.11.013

Figure 2.

Figure 2.

Hazard ratios for risk of all-cause hospitalization between SGLT2i vs. DPP4i (a), CVD hospitalization between SGLT2i vs. DPP4i (b), all-cause hospitalization between GLP1RA vs. DPP4i (c), and CVD hospitalization between GLP1RA vs. DPP4i (d) by age, sex, eGFR, ACR, and history of CVD. *p for interaction<0.05.

ACR= albumin creatinine ratio; CVD=cardiovascular disease; DPP4i= dipeptidyl peptidase-4 inhibitors; eGFR= estimated glomerular filtration rate; GLP1RA=glucagon-like peptide 1 receptor agonists; SGLT2i=sodium glucose-cotransporter 2 inhibitors.